

Supplementary Tables

Table S1. Flow cytometric immunophenotype of the neoplastic population identified in aspirates of (a) mediastinal mass at initial presentation and (b) inguinal and prescapular lymph nodes at relapse (Day 90 after diagnosis).

Time point	CD21	CD3	CD4	CD5	CD8
(a) Initial presentation	-	+	+	+	-
(b) Relapse	-	-	+	+	-

Table S2. Predicted drug sensitivity profile generated by the AI-integrated *ex vivo* assay.

Drug tested	Predicted priority	Prediction score	95% Confidence Interval
Cyclophosphamide	1	0.78	0.72–0.85
Mechlorethamine	2	0.69	0.61–0.75
Prednisone	3	0.63	0.57–0.70
Lomustine	4	0.61	0.54–0.68
L-Asparaginase	5	0.58	0.51–0.64
Vincristine	6	0.51	0.45–0.58
Doxorubicin	7	0.43	0.37–0.50
Tanovea	8	0.40	0.33–0.46
Vinblastine	9	0.39	0.34–0.46
Chlorambucil	10	0.37	0.28–0.41
Dexamethasone	11	0.36	0.30–0.45
Mitoxantrone	12	0.36	0.29–0.41